Sonoma Pharmaceuticals Inc <SNOA.OQ> expected to post a loss of 69 cents a share - Earnings Preview
Sonoma Pharmaceuticals Inc SNOA.OQ SNOA.O is expected to show a rise in quarterly revenue when it reports results on February 6 (estimated) for the period ending December 31 2024
The Boulder Colorado-based company is expected to report a 29.4% increase in revenue to $4.06 million from $3.14 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Sonoma Pharmaceuticals Inc is for a loss of 69 cents per share.
The one available analyst rating on the shares is "strong buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $17.00, above its last closing price of $2.58.
This summary was machine generated February 4 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
[U.S. IPO] Valuation Doubles Figma’s Pre-IPO Level — Canva’s Latest Funding Hints at Public Market Debut
TradingKey - Following the strong market reception of design collaboration platform Figma’s IPO, which has reignited momentum for software company listings, another online design platform, Canva, appears to be preparing for a potential public offering.
Two Key Things to Watch in Walmart’s Q2 Earnings: Tariff Pressure and E-Commerce Momentum
TradingKey - U.S. retailer Walmart (WMT) will release its Q2 2026 fiscal earnings before the market opens on August 21. As a key barometer of the U.S. economy and consumer health, Walmart’s results will reveal how tariffs are impacting consumer behavior and corporate profits. Another focus is
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...
